S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
West rejects Putin's claim it sabotaged Baltic gas pipelines
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
West rejects Putin's claim it sabotaged Baltic gas pipelines
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
West rejects Putin's claim it sabotaged Baltic gas pipelines
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
West rejects Putin's claim it sabotaged Baltic gas pipelines
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
NYSEAMERICAN:LCTX

Lineage Cell Therapeutics - LCTX Stock Forecast, Price & News

$1.13
-0.02 (-1.74%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.13
$1.18
50-Day Range
N/A
52-Week Range
$1.10
$2.71
Volume
184,655 shs
Average Volume
261,487 shs
Market Capitalization
$191.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Lineage Cell Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
431.0% Upside
$6.00 Price Target
Short Interest
Healthy
2.62% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.75 out of 5 stars

LCTX stock logo

About Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Receive LCTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lineage Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

LCTX Stock News Headlines

LCTX Lineage Cell Therapeutics, Inc.
Earnings Preview: Lineage Cell Therapeutics
Lineage Cell (LCTX) Reports Q4 Loss
See More Headlines
Receive LCTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lineage Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

LCTX Company Calendar

Last Earnings
11/10/2021
Today
10/01/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:LCTX
CIK
N/A
Employees
57
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+431.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-43,020,000.00
Net Margins
-382.15%
Pretax Margin
-382.59%

Debt

Sales & Book Value

Annual Sales
$4.34 million
Book Value
$0.54 per share

Miscellaneous

Free Float
124,430,000
Market Cap
$191.83 million
Optionable
Optionable
Beta
1.59

Key Executives

  • Mr. Brian M. Culley M.A. (Age 51)
    M.B.A., CEO, Pres, Interim CFO, Principal Financial Officer & Director
    Comp: $913.5k
  • Mr. George A. Samuel III (Age 41)
    J.D., Gen. Counsel & Company Sec.
    Comp: $175.63k
  • Ms. Alexandra Hernandez
    Interim Principal Accounting Officer, Sr. Director of Fin. & Controller
  • Ioana C. Hone
    Director of Investor Relations
  • Dr. Gary S. Hogge D.V.M. (Age 53)
    Dvm, Ms, Ph.D., Sr. VP of Clinical & Medical Affairs
  • Ms. Brandi L. Roberts CPA (Age 48)
    M.B.A., Consultant
  • Mr. William Annett (Age 68)
    Pres & CEO of OncoCyte Corp.
  • Dr. Rami Skaliter (Age 64)
    Chief Exec. Officer of Cell Cure Neurosciences Ltd.
  • Dr. Harold D. Waitz (Age 80)
    VP of Regulatory Affairs & Quality Control













LCTX Stock - Frequently Asked Questions

Should I buy or sell Lineage Cell Therapeutics stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lineage Cell Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LCTX shares.
View LCTX analyst ratings
or view top-rated stocks.

What is Lineage Cell Therapeutics' stock price forecast for 2022?

5 Wall Street analysts have issued 12 month price objectives for Lineage Cell Therapeutics' shares. Their LCTX share price forecasts range from $4.00 to $8.00. On average, they expect the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 431.0% from the stock's current price.
View analysts price targets for LCTX
or view top-rated stocks among Wall Street analysts.

How have LCTX shares performed in 2022?

Lineage Cell Therapeutics' stock was trading at $1.78 at the beginning of the year. Since then, LCTX shares have decreased by 36.5% and is now trading at $1.13.
View the best growth stocks for 2022 here
.

Are investors shorting Lineage Cell Therapeutics?

Lineage Cell Therapeutics saw a decrease in short interest in August. As of August 15th, there was short interest totaling 4,480,000 shares, a decrease of 7.4% from the July 31st total of 4,840,000 shares. Based on an average trading volume of 839,700 shares, the short-interest ratio is presently 5.3 days.
View Lineage Cell Therapeutics' Short Interest
.

When is Lineage Cell Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our LCTX earnings forecast
.

How were Lineage Cell Therapeutics' earnings last quarter?

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) issued its earnings results on Wednesday, November, 10th. The company reported ($0.05) EPS for the quarter, meeting the consensus estimate of ($0.05). The firm earned $2.27 million during the quarter, compared to analysts' expectations of $0.56 million. Lineage Cell Therapeutics had a negative net margin of 382.15% and a negative trailing twelve-month return on equity of 32.03%.

What other stocks do shareholders of Lineage Cell Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lineage Cell Therapeutics investors own include Matinas BioPharma (MTNB), Bionano Genomics (BNGO), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Novan (NOVN), Pennsylvania Real Estate Investment Trust (PEI), CNBX Pharmaceuticals (CNBX), Enerplus (ERF), KushCo (KSHB) and Zosano Pharma (ZSAN).

What is Lineage Cell Therapeutics' stock symbol?

Lineage Cell Therapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "LCTX."

How do I buy shares of Lineage Cell Therapeutics?

Shares of LCTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lineage Cell Therapeutics' stock price today?

One share of LCTX stock can currently be purchased for approximately $1.13.

How much money does Lineage Cell Therapeutics make?

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) has a market capitalization of $191.83 million and generates $4.34 million in revenue each year. The company earns $-43,020,000.00 in net income (profit) each year or ($0.30) on an earnings per share basis.

How can I contact Lineage Cell Therapeutics?

Lineage Cell Therapeutics' mailing address is 2173 SALK AVENUE SUITE 200, CARLSBAD CA, 92008. The official website for the company is www.lineagecell.com. The company can be reached via phone at (510) 521-3390, via email at ir@lineagecell.com, or via fax at 510-521-3389.

This page (NYSEAMERICAN:LCTX) was last updated on 10/1/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.